Demant Crescita futura

Future criteri di controllo 4/6

Demant prevede che gli utili e i ricavi cresceranno rispettivamente di 12.4% e 6.1% all'anno. Si prevede che l'EPS crescerà di 15.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 28.1% in 3 anni.

Informazioni chiave

12.4%

Tasso di crescita degli utili

15.5%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	19.0%
Tasso di crescita dei ricavi	6.1%
Rendimento futuro del capitale proprio	28.1%
Copertura analitica	Good
Ultimo aggiornamento	20 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

WBAG:DEMA - Stime future degli analisti e dati finanziari passati (DKK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	25,845	3,453	3,460	4,656	15
12/31/2025	24,035	3,075	3,148	4,202	17
12/31/2024	22,427	2,490	2,699	3,671	15
6/30/2024	22,836	2,535	2,836	3,644	N/A
3/31/2024	22,640	2,544	3,130	3,957	N/A
12/31/2023	22,443	2,552	3,424	4,270	N/A
9/30/2023	21,442	2,577	2,932	3,815	N/A
6/30/2023	20,902	2,488	2,462	3,387	N/A
3/31/2023	20,304	2,381	1,954	2,878	N/A
12/31/2022	19,705	2,274	1,445	2,369	N/A
9/30/2022	19,181	2,460	1,581	2,472	N/A
6/30/2022	18,656	2,645	1,716	2,575	N/A
3/31/2022	18,281	2,671	2,135	2,927	N/A
12/31/2021	17,905	2,696	2,553	3,279	N/A
9/30/2021	17,521	2,453	2,663	3,341	N/A
6/30/2021	17,137	2,209	2,772	3,403	N/A
3/31/2021	15,803	1,665	2,356	3,012	N/A
12/31/2020	14,469	1,121	1,940	2,621	N/A
9/30/2020	14,072	970	1,507	2,226	N/A
6/30/2020	13,674	818	1,073	1,831	N/A
3/31/2020	14,310	1,140	1,228	1,990	N/A
12/31/2019	14,946	1,462	1,383	2,149	N/A
9/30/2019	14,728	1,579	1,218	1,942	N/A
6/30/2019	14,510	1,695	1,052	1,734	N/A
3/31/2019	14,224	1,759	1,059	1,709	N/A
12/31/2018	13,937	1,823	1,065	1,683	N/A
9/30/2018	13,699	1,836	1,268	1,833	N/A
6/30/2018	13,461	1,849	1,471	1,982	N/A
3/31/2018	13,325	1,802	N/A	1,927	N/A
12/31/2017	13,189	1,754	N/A	1,872	N/A
9/30/2017	12,943	1,689	N/A	1,855	N/A
6/30/2017	12,697	1,624	N/A	1,837	N/A
3/31/2017	12,350	1,542	N/A	1,758	N/A
12/31/2016	12,002	1,459	N/A	1,679	N/A
9/30/2016	11,717	1,429	N/A	1,622	N/A
6/30/2016	11,432	1,399	N/A	1,565	N/A
3/31/2016	11,049	1,418	N/A	1,579	N/A
12/31/2015	10,665	1,436	N/A	1,592	N/A
9/30/2015	10,258	1,402	N/A	1,568	N/A
6/30/2015	9,850	1,367	N/A	1,544	N/A
3/31/2015	9,598	1,347	N/A	1,520	N/A
12/31/2014	9,346	1,326	N/A	1,495	N/A
9/30/2014	9,221	1,301	N/A	1,380	N/A
6/30/2014	9,095	1,275	N/A	1,265	N/A
3/31/2014	9,027	1,280	N/A	1,274	N/A
12/31/2013	8,959	1,285	N/A	1,282	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di DEMA ( 12.4% all'anno) è superiore al tasso di risparmio ( 1.4% ).

Guadagni vs Mercato: Si prevede che gli utili di DEMA ( 12.4% all'anno) cresceranno più rapidamente del mercato Austrian ( 8.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di DEMA cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di DEMA ( 6.1% all'anno) crescerà più rapidamente del mercato Austrian ( 0.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DEMA ( 6.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di DEMA sarà elevato tra 3 anni ( 28.1 %)

Demant Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Demant A/S Updates Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2023

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Demant A/S Revises Earnings Guidance for the Full Year 2022

Demant A/Sreiterated Guidance for the Year 2021

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

First half 2024 earnings released: EPS: kr.6.18 (vs kr.6.14 in 1H 2023)

Demant A/S Updates Earnings Guidance for the Year 2024

Investor sentiment deteriorates as stock falls 16%

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Demant A/S Provides Earnings Guidance for the Year 2024

Now 21% undervalued

Full year 2023 earnings released: EPS: kr.11.43 (vs kr.10.06 in FY 2022)

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Now 20% undervalued

Demant A/S Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Now 20% undervalued

First half 2023 earnings released: EPS: kr.5.63 (vs kr.5.07 in 1H 2022)

Now 21% undervalued after recent price drop

Now 21% undervalued

Demant A/S Announces Executive Changes

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr.10.06 (vs kr.10.70 in FY 2021)

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Demant A/S Revises Earnings Guidance for the Full Year 2022

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Now 20% undervalued after recent price drop

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 21% undervalued after recent price drop

Demant A/S Announces Update on Voluntary Field Corrective Action

Demant A/Sreiterated Guidance for the Year 2021

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: €35.34

New 90-day high: €31.77

Demant Launches New Flagship Hearing aids

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita